

# Biofrontera AG (B8F) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/BEA6D85F24FEN.html

Date: November 2021

Pages: 49

Price: US\$ 125.00 (Single User License)

ID: BEA6D85F24FEN

## **Abstracts**

Biofrontera AG (B8F) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.



Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## **Highlights**

Biofrontera AG (Biofrontera) is a biopharmaceutical company that develops and markets dermatological medications and medical cosmetics. The company's products comprises of Ameluz, BF-RhodoLED, Xepi, Aktipak and Belixos. Its prescription drug Ameluz is used for the treatment of skin disease actinic keratosis. Biofrontera's BF-RhodoLED is a lamp used for photodynamic therapy with LEDs emitting red light. Belixos is a cosmetic product, indicated for regenerative care of reddened and inflamed skin. Its Belixos line of products include Belixos creme, Belixos liquid, Belixos gel, and Belixos protect. The company distributes its products through pharmaceutical wholesalers and licensing partners. Biofrontera is headquartered in Leverkusen, Germany.

Biofrontera AG Key Recent Developments

Nov 18,2021: Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021

Oct 01,2021: Biofrontera reports preliminary approximate revenues for the month of September 2021

Sep 08,2021: Biofrontera reports preliminary revenue for the month of August 2021 Aug 19,2021: Biofrontera reports financial results for the six months ended June 30,



2021

Aug 09,2021: Biofrontera reports preliminary revenue for the month of July 2021

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.



Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



## **Contents**

#### **SECTION 1 - ABOUT THE COMPANY**

Biofrontera AG - Key Facts

Biofrontera AG - Key Employees

Biofrontera AG - Key Employee Biographies

Biofrontera AG - Major Products and Services

Biofrontera AG - History

Biofrontera AG - Company Statement

Biofrontera AG - Locations And Subsidiaries

**Head Office** 

Other Locations & Subsidiaries

#### **SECTION 2 – COMPANY ANALYSIS**

Company Overview

Biofrontera AG - Business Description

Geographical Segment: Europe

Performance

Geographical Segment: Germany

Performance

Geographical Segment: Other regions

Performance

Geographical Segment: The US

Performance R&D Overview

Biofrontera AG - SWOT Analysis

SWOT Analysis - Overview

Biofrontera AG - Strengths

Biofrontera AG - Weaknesses

Biofrontera AG - Opportunities

Biofrontera AG - Threats

Biofrontera AG - Key Competitors

#### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios



Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

#### SECTION 4 - COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021 Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021 Biofrontera AG, Recent Deals Summary

#### **SECTION 5 – COMPANY'S RECENT DEVELOPMENTS**

Nov 18, 2021: Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021

Oct 01, 2021: Biofrontera reports preliminary approximate revenues for the month of September 2021

Sep 08, 2021: Biofrontera reports preliminary revenue for the month of August 2021 Aug 19, 2021: Biofrontera reports financial results for the six months ended June 30, 2021

Aug 09, 2021: Biofrontera reports preliminary revenue for the month of July 2021 Jul 06, 2021: Biofrontera reports preliminary revenue for the month of June 2021 Jun 07, 2021: Biofrontera reports preliminary revenue for the month of May 2021

May 11, 2021: Biofrontera reports Q1 2021 financial results

Apr 12, 2021: Biofrontera reports results for the 2020 financial year

Mar 31, 2021: Biofrontera announces conference call to be held on April 13, 2021 to discuss fiscal year 2020 financial results

#### **SECTION 6 – APPENDIX**

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer



## **List Of Tables**

#### LIST OF TABLES

Biofrontera AG, Key Facts

Biofrontera AG, Key Employees

Biofrontera AG, Key Employee Biographies

Biofrontera AG, Major Products and Services

Biofrontera AG, History

Biofrontera AG, Subsidiaries

Biofrontera AG, Key Competitors

Biofrontera AG, Ratios based on current share price

Biofrontera AG, Annual Ratios

Biofrontera AG, Annual Ratios (Cont...1)

Biofrontera AG, Annual Ratios (Cont...2)

Biofrontera AG, Interim Ratios

Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Biofrontera AG, Recent Deals Summary

**Currency Codes** 

**Capital Market Ratios** 

**Equity Ratios** 

**Profitability Ratios** 

**Cost Ratios** 

Liquidity Ratios

Leverage Ratios

**Efficiency Ratios** 



## **List Of Figures**

### **LIST OF FIGURES**

Biofrontera AG, Performance Chart (2016 - 2020)

Biofrontera AG, Ratio Charts

Biofrontera AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Biofrontera AG, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



#### I would like to order

Product name: Biofrontera AG (B8F) - Financial and Strategic SWOT Analysis Review

Product link: <a href="https://marketpublishers.com/r/BEA6D85F24FEN.html">https://marketpublishers.com/r/BEA6D85F24FEN.html</a>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

## **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/BEA6D85F24FEN.html">https://marketpublishers.com/r/BEA6D85F24FEN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

i iiot iiaiiio.		
Last name:		
Email:		
Company:		
Address:		
City:		
Zip code:		
Country:		
Tel:		
Fax:		
Your message:		
	**All fields are required	
	Custumer signature	

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970